Pulmonology

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

U.S. News & World Report Names MemorialCare Miller Children's & Women's Hospital Long Beach Among Best in Nation for Pediatric Pulmonology and Lung Surgery

Retrieved on: 
Wednesday, June 21, 2023
U.S. News & World Report Best Hospitals Rankings, Pacific Ocean, Culture, Parent, Hospital, U.S, Pulmonology, Medicine, RTI, Patient, Health, News, RTI International, Nursing, U.S. News & World Report

LONG BEACH, Calif., June 21, 2023 /PRNewswire/ -- MemorialCare Miller Children's & Women's Hospital Long Beach has been nationally ranked #40 as a 2023-2024 Best Hospital for Pediatric Pulmonology and Lung Surgery, according to the U.S. News & World Report.

Key Points: 
  • LONG BEACH, Calif., June 21, 2023 /PRNewswire/ -- MemorialCare Miller Children's & Women's Hospital Long Beach has been nationally ranked #40 as a 2023-2024 Best Hospital for Pediatric Pulmonology and Lung Surgery, according to the U.S. News & World Report.
  • Miller Children's & Women's Hospital was also ranked among the top 10 regionally in the state and 12th in the Pacific Region covering Alaska, Washington, Oregon, California, and Hawaii.
  • "Being named one of the nation's best children's hospitals in pediatric pulmonary is a testament to the dedication our team has for clinical excellence," says Graham Tse, M.D., chief medical officer, MemorialCare Miller Children's & Women's Hospital Long Beach.
  • "Being nationally, state-wide and regionally ranked reflects on the culture of Miller Children's & Women's," says Yair Katz, chief executive, Miller Children's & Women's Hospital Long Beach.

Children’s Hospital Los Angeles: Still the Best Pediatric Care in California and the West Coast

Retrieved on: 
Wednesday, June 21, 2023
Managed Care, Other Health, General Health, Philanthropy, Family, Consumer, Hospitals, Fund Raising, Foundation, Parenting, Children, Women, Health, Children's Hospital Los Angeles, Heart, Anti Additive Association, Arm, Hospital, CHLA, Best, EST, Multimedia, Research, RTI, U.S. News & World Report, Pulmonology, Patient, Physician, Journal of Neurology, Neurosurgery, and Psychiatry, Nursing, Cardiology, Master of Science, Child, Gastroenterology, City, Digestive system surgery, News, Safety, Scoliosis, RTI International, Dentistry, Orthopedic surgery, Cancer, Nephrology, MD, Neonatology, Urology

It is the blueprint behind CHLA’s unbroken streak as California’s top hospital for pediatric care according to U.S. News & World Report, which today released the 2023-24 edition of its annual Best Children's Hospitals rankings.

Key Points: 
  • It is the blueprint behind CHLA’s unbroken streak as California’s top hospital for pediatric care according to U.S. News & World Report, which today released the 2023-24 edition of its annual Best Children's Hospitals rankings.
  • View the full release here: https://www.businesswire.com/news/home/20230620566343/en/
    Children's Hospital Los Angeles is once again the No.
  • 1 children's hospital in California and on the West Coast.
  • (Photo: Business Wire)
    For the 15th straight year, CHLA has been named to U.S. News’ prestigious Honor Roll of Best Children’s Hospitals .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Retrieved on: 
Sunday, June 18, 2023
LLP, ARS, NDA, Translation, Pulmonology, Patient, Anaphylaxis, Adrenaline, FDA, Pomerantz, News, Food, Safety, Cryptocurrency, Pharmaceutical industry

NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).

Key Points: 
  • NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Children’s Hospital Los Angeles and Los Angeles Unified School District Partner to Offer Telehealth Visits from School with CHLA Specialists

Retrieved on: 
Wednesday, June 14, 2023
Technology, Children, Hospitals, Other Technology, Telemedicine, Virtual Medicine, General Health, Consumer, Health, Primary, Secondary, Education, Adolescent medicine, Children's Hospital Los Angeles, Heart, Superintendent of the Los Angeles Unified School District, Telehealth, Partnership, Travel, Caregiver, Medicine, CHLA, COVID-19, Privacy, School, Student, Patient, Child, National Blue Ribbon Schools Program, Digital, Immunology, MPH, Medical genetics, Nursing, Hospital, Pulmonology, Endocrinology

In a first-of-its-kind partnership between a hospital and a local school district, Children's Hospital Los Angeles (CHLA) and Los Angeles Unified School District have joined together to offer virtual healthcare visits for children at school through the Virtual Care at School Program.

Key Points: 
  • In a first-of-its-kind partnership between a hospital and a local school district, Children's Hospital Los Angeles (CHLA) and Los Angeles Unified School District have joined together to offer virtual healthcare visits for children at school through the Virtual Care at School Program.
  • The program aims to create a personalized and convenient way for children to receive care at school from CHLA specialists in lieu of being absent for an appointment.
  • “The partnership with Children’s Hospital Los Angeles, the largest provider of pediatric medical care in Los Angeles County, will not only provide world-class care from CHLA specialists.
  • Los Angeles Unified identified the following 20 schools to pilot the program based on an in-depth analysis of absenteeism rates and the number of students with chronic conditions at each school.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Retrieved on: 
Sunday, May 28, 2023
LLP, ARS, NDA, Translation, Pulmonology, Patient, Anaphylaxis, Adrenaline, FDA, Pomerantz, News, Food, Safety, Pharmaceutical industry

NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).

Key Points: 
  • NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Retrieved on: 
Tuesday, May 23, 2023
Tissue, BMC, CHRP, Fibrosis, Idiopathic pulmonary fibrosis, Therapy, Macrophage, Pharmacy, BioMed Central, Oxygen, ATS, COVID-19, MTCC, ILD, McMaster, Department of Chemical Engineering, Imperial College London, Lung, Pulmonology, Blood, YBG, Canada Research Chair, Chemical substance, American Thoracic Society, Asilomar International Conference on Climate Intervention Technologies, GDP, McMaster University, Mouse, Principal, Particle size, IPF, Chemical engineering, CZO, Conference, Treatment, Disease, Pharmaceutical industry, Medical device, Vaccine, Medicine

EDMONTON, Alberta, May 23, 2023 (GLOBE NEWSWIRE) --  Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).

Key Points: 
  • ILD damages the tissues between the small air sacs in the lungs (alveoli) and the blood vessels around them.
  • ILD represent a significant unmet medical need and is currently putting a major strain on healthcare systems around the globe.
  • Prior to the pandemic, Ceapro and accomplished researchers from McMaster University teamed up to develop a novel drug formulation for the potential treatment of IPF.
  • We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Retrieved on: 
Monday, May 22, 2023
LLP, ARS, NDA, Translation, Pulmonology, Patient, Anaphylaxis, Adrenaline, FDA, Pomerantz, News, Food, Safety, Pharmaceutical industry

NEW YORK, May 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).

Key Points: 
  • NEW YORK, May 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

bioAffinity Technologies Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Use, Compensator (control theory), Journal of Visualized Experiments, Marketing, Respiratory Research, Clinical trial, Lung cancer, Receiver operating characteristic, Pulmonology, BIAF, Research, Lung, IPO, Flow cytometry, Treating, Patient, Physician, European, CFO, FDA, Therapy, Medical imaging, Medical device, Pharmaceutical industry, ROC

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.
  • Highlights from the first quarter of 2023 and subsequent weeks included:
    Appointed Michael Dougherty as Chief Financial Officer.
  • Research and development expenses were $370,000 for the first quarter of 2023, compared with $280,000 for the comparable period in 2022.
  • Clinical development expenses were $20,000 for the first quarter of 2023, compared with $53,000 for the first quarter of 2022.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Retrieved on: 
Friday, May 12, 2023
LLP, ARS, NDA, Translation, Pulmonology, Patient, Anaphylaxis, Adrenaline, FDA, Pomerantz, News, Food, Safety, Pharmaceutical industry

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).

Key Points: 
  • NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.